Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies

NCT00689065 is registered in ClinicalTrials.gov with Calando Pharmaceuticals as lead sponsor.

NCT NCT00689065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00689065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies
Lead sponsor
Calando Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2008
Completion date
September 30, 2012
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor